



ISSN NO. 2320-5407

ISSN(O): 2320-5407 | ISSN(P): 3107-4928

# International Journal of Advanced Research

**Publisher's Name: Jana Publication and Research LLP**

*www.journalijar.com*

## REVIEWER'S REPORT

Manuscript No.: IJAR-56576

Title: Lybalvi (Olanzapine and Samidorphan) in the management of schizoaffective disorder in an adult with Prader-Willi syndrome

### Recommendation:

- Accept as it is .....
- ✓ **Accept after minor revision.....**
- Accept after major revision .....
- Do not accept (*Reasons below*) .....

Rating	Excel.	Good	Fair	Poor
Originality		✓		
Techn. Quality		✓		
Clarity		✓		
Significance	✓			

Reviewer Name: Dr S. K. Nath

### *Detailed Reviewer's Report*

#### Strengths of the Study

- **Originality:** The case report presents a novel application of Lybalvi for managing psychiatric symptoms in a patient with Prader-Willi syndrome, a population with limited research on safe and effective psychotropic treatments.
- **Relevance:** Addresses a critical clinical challenge in treating psychiatric comorbidities in Prader-Willi syndrome, especially considering the risks associated with weight gain from antipsychotics.
- **Contribution to the Field:** Provides a real-world example indicating potential of olanzapine-samidorphan combination therapy to control psychotic symptoms while minimizing metabolic side effects, encouraging further research.
- **Methodology:** Detailed case description, including symptom evolution, treatment trials, and clinical response, offering practical insights for clinicians.

#### Weaknesses of the Study

- **Sample Size:** As a single case report, the findings lack generalizability to the broader PWS population.
- **Limited Data:** No systematic assessment of metabolic parameters or long-term follow-up provided.
- **Absence of Control or Comparison Group:** Cannot establish causality or superiority over other treatments.
- **Potential Biases:** Clinical response may be influenced by other confounders not controlled or documented.
- **Methodological Limitations:** Lacks standardized scales for symptom severity or metabolic assessment; reliance on subjective clinical impressions.
- **Reporting of Ethical Approvals:** No explicit mention of ethical approval or informed consent obtained for publishing the case, which may be required depending on institutional policies.

#### Reviewer Comments

- **Title and Abstract:** The title clearly reflects the core focus; however, the abstract could improve clarity by explicitly stating the significance and limitations of this case report. Also, including the duration of follow-up would strengthen the abstract.

# International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

*www.journalijar.com*

---

## REVIEWER'S REPORT

- **Introduction and Objectives:** The introduction offers a comprehensive overview of PWS and associated psychiatric challenges. The objective demonstrating the potential use of Lybalvi is implicit but could be more explicitly stated.
- **Methodology and Statistical Analysis:** As a case report, formal statistical analysis was not applicable; nonetheless, systematic assessment tools and metabolic monitoring would enhance rigor. Ethical considerations are not explicitly addressed.
- **Results and Discussion:** Results are descriptively presented; however, quantification of symptom changes through validated scales would add depth. The discussion adeptly contextualizes findings within existing literature but could better acknowledge the limitations inherent in a single case.
- **Conclusion and Implications:** Conclusions are appropriate but should caution about the limited evidence level and recommend cautious interpretation.
- **Ethical Clearance:** The manuscript does not mention obtaining ethical approval or patient consent. Clarification on this point is necessary.
- **Language and Formatting:** The manuscript has minor grammatical issues and punctuation inconsistencies that could be improved for clarity. References are generally adequate but could be formatted uniformly according to journal guidelines.
- **Figures/Tables:** The manuscript lacks visual data; including clinical charts or follow-up metabolic parameters could aid comprehension.